BrainsWay Ltd. (BWAY)
9.90
0.47 (4.98%)
At close: Jan 14, 2025, 3:59 PM
9.89
-0.10%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 9.65 |
| Market Cap | 186.28M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.08 |
| PE Ratio (ttm) | 123.75 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 10 |
| Volume | 97,263 |
| Avg. Volume (20D) | 76,100 |
| Open | 9.80 |
| Previous Close | 9.43 |
| Day's Range | 9.80 - 10.23 |
| 52-Week Range | 4.61 - 10.98 |
| Beta | undefined |
About BWAY
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chro...
Industry Medical - Devices
Sector Healthcare
IPO Date Apr 17, 2019
Employees 134
Stock Exchange NASDAQ
Ticker Symbol BWAY
Website https://www.brainsway.com
Analyst Forecast
According to 3 analyst ratings, the average rating for BWAY stock is "Buy." The 12-month stock price forecast is $12.5, which is an increase of 26.26% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
BrainsWay Ltd. is scheduled to release its earnings on Mar 5, 2025,
before market opens.
Analysts project revenue of $10.80M, reflecting a 19.61% YoY growth and earnings per share of 0.02.
Analysts project revenue of $10.80M, reflecting a 19.61% YoY growth and earnings per share of 0.02.
3 months ago ·
Source
+14.5%
BrainsWay shares are trading higher after the comp...
Unlock content with
Pro Subscription
